Genmab — Juli 2020
-
Could be this one : https://www.clinicaltrials.gov/ct2/show/NCT03473730
-
FDA grants Breakthrough Therapy Designation for Roche’s CD20xCD3 bispecific cancer immunotherapy mosunetuzumab recognising its potential in follicular lymphoma
-
FDA grants Breakthrough Therapy Designation for Roche’s CD20xCD3 bispecific cancer immunotherapy mosunetuzumab recognising its potential in follicular lymphoma
This designation is based on results from the phase I/Ib GO29781 study that showed mosunetuzumab demonstrated high response rates and durable complete remissions in people with relapsed or refracto...
(www.roche.com)
-
Flot rebound af Genmab. NOVO og ZEAL bliver stående på perronen.
-
Det holdt nu ikke mange timer.
-
Mcjean...du tjekker bare her. https://www.proinvestor.com/chathistory/-120/finanskalender
-
Velbekommen.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind